TIGIT and glioblastoma: This study unveiled a powerful pathway to exploiting TIGIT activity while overcoming the divergent responses induced by its mere blockade, and demonstrated that iNK cells engineered to release a localized multi-targeted checkpoint blockade can elicit effective anti-GBM activity, relying upon the natural cytotoxicity of the iPSC-NK cells, without any additional CAR signaling.